Treatments for tuberculosis and non-tuberculous mycobacterial infections: dual-targeted rifamycin-AAP conjugates (RifaAAPs)
collapse; }
Invention Summary:
RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains.
Researchers indicate that...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
ANTIBACTERIAL AGENTS: DUAL-TARGETED RNA POLYMERASE INHIBITORS (BENZOXAZINO-RIFAAAPS
Invention Summary:
RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains.
Researchers indicate that RifaAAPs comprise...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Infectious Disease, Technology Classifications > Healthcare & Life Sciences
|
ANTIBACTERIAL AGENTS: CO-SOLVENT-FREE, SURFACTANT-FREE FORMULATIONS OF PYRONINS
Invention Summary:
APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains.
Our researchers have indicated...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
ANTIBACTERIAL AGENTS: O-ALKYL-DEUTERATED PYRONINS (PYS) AND ARYL PYRONINS (APYS)
Invention Summary:
APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains.
Our researchers have indicated...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
Treatments for drug-susceptible and drug-resistant bacterial infections: arylmyxopyronins (APYs)
Invention Summary:
APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains.
Our researchers have indicated...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease
|
Therapeutics for Drug-Resistant Bacterial Infections - Myxopyronins
Invention Summary:
APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains.
Our researchers have indicated...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Juan Shen, James Bacci, William Solvible, Christopher Self, Gary Olson, Yon Ebright, Anne-Cecile Hiebel
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
Therapeutics for Drug-Resistant Bacterial Infections: Inhibitors of Bacterial RNA Polymerase
Invention Summary:
Bacterial infectious diseases kill 100,000 persons each year in the US and 11 million persons each year worldwide, representing nearly a fifth of deaths each year worldwide. For six decades, antibiotics have been our bulwark against bacterial infectious diseases. However, now this bulwark is collapsing. For all major bacterial...
Published: 7/7/2023
|
Inventor(s): Richard Ebright, Yu Feng, Yu Zhang
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
Treatments for tuberculosis and non-tuberculous mycobacterial infections: N-aroyl-N-aryl-phenylalaninamides (AAPs)
Invention Summary:
AAPs are novel orally available compounds for treatment for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi‑drug‑resistant (MDR), and extensively-drug-resistant (XDR) strains.
Researchers indicate that AAPs potently inhibit mycobacterial RNA polymerase...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright, Soma Mandal
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|